Patients with atopic dermatitis maintain positive outcomes with reduced dupilumab dosages

Patients with persistently controlled atopic dermatitis continued to experience stable and low disease activity after receiving reduced dosages of dupilumab, according to a study published in Allergy.These findings show that patient-centered dosing regimens can be successful, Lotte S. Spekhorst, MD, of the department of dermatology and allergology and National Expertise Center for Atopic

Related Keywords

Netherlands ,Utrecht ,Lottes Spekhorst ,Sanofi Genzyme Regeneron ,Atopic Dermatitis At University Center Utrecht ,National Expertise Center ,Rating Scale ,Atopic Dermatitis ,University Center Utrecht ,Eczema Area ,Severity Index ,Numeric Rating Scale ,